Literature DB >> 7058985

Preoperative use of 5-fluorouracil suppository for carcinoma of the rectum.

T Takahashi, K Kohno, T Yamaguchi, T Narisawa.   

Abstract

A total of 50 patients with carcinoma of the rectum were treated with 5-fluorouracil suppository before operation. The suppository, which was made of Witepsol suppository base containing 5-fluorouracil, yielded high drug concentrations in carcinoma, draining blood and regional lymph nodes. As a clinical response to the suppository, a significant decrease in the size of tumor mass was noted in 8 of 50 carcinomas, but in other cases the gross change was unmeasurable. Thirty-three percent of the surgically resected carcinomas were histologically judged to have responded to the suppository. In such cases, histologic changes correlated well with the total dose of 5-fluorouracil. The adverse effects of the suppository were confined to anal pain, tenesmus and anal bleeding, probably due to the topical effect of 5-fluorouracil on the rectal mucosa.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7058985     DOI: 10.1016/0002-9610(82)90062-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.

Authors:  H Horie; H Kashiwagi; F Konishi; K Furuta; A Ozawa; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Suppository delivery of 5-fluorouracil in rectal cancer.

Authors:  S Galandiuk; W Wrightson; L Marr; S Myers; R V LaRocca
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

3.  The antitumor activity and immunosuppressive effects of 5-fluorouracil suppositories in rectal cancer patients.

Authors:  W Adachi; A Sugenoya; N Horigome; C Takahashi; F Iida; J Nakayama
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

4.  Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer.

Authors:  T Takahashi; H Horie; O Kojima; M Itoh
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers.

Authors:  C Sakakura; K Koide; D Ichikawa; T Wakasa; M Shirasu; A Kimura; H Taniguchi; A Hagiwara; T Yamaguchi; J Inazawa; T Abe; T Takahashi; E Otsuji
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

6.  Increased apoptosis rate by hyperthermochemoradiotherapy for advanced rectal cancers.

Authors:  C Sakakura; K Koide; M Shirasu; D Ichikawa; M Wakasa; M Ogaki; J Yamazaki; J Inazawa; T Abe; H Taniguchi; A Hagiwara; T Yamaguchi; T Takahashi
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

7.  Development of in situ gelling and bio adhesive 5-Fluorouracil enema.

Authors:  Lu-Lu Wang; Wen-Sheng Zheng; Shao-Hua Chen; Xia-Qin Fang
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  In situ delivery of thermosensitive gel-mediated 5-fluorouracil microemulsion for the treatment of colorectal cancer.

Authors:  Lu-Lu Wang; Shuai Huang; Hui-Hui Guo; Yan-Xing Han; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Des Devel Ther       Date:  2016-09-08       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.